Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
Langue
Français
Tacrolimus Dosing Optimization for Allogeneic Transplant Patients Receiving Post-Transplant Cyclophosphamide | Synapse
March 3, 2026
Tacrolimus Dosing Optimization for Allogeneic Transplant Patients Receiving Post-Transplant Cyclophosphamide
BL
Ben Lorge
LS
Lisa Samanas
Froedtert Hospital
EA
Emilie Aschenbrenner
See all
Key Points
Improved tacrolimus dosing results in better immunosuppression in patients undergoing allogeneic transplant.
Key evidence shows that optimized dosing reduces complications associated with transplant procedures.
Observational analysis across multiple transplant centers assessed dosing strategies post-transplant.
This suggests a need for refined dosing protocols, particularly for patients receiving post-transplant cyclophosphamide.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Lorge et al. (Sun,) studied this question.
synapsesocial.com/papers/69a7602cc6e9836116a2ca7c
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.941